Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis [clinicaltrials:NCT01603056]

Bio2RDF identifier

NCT01603056

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01603056

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01603056

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

617

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01603056 arm group 3bddaebce971dc4a5494b4d826838f94 [clinicaltrials_resource:NCT01603056/arm-group/3bddaebce971dc4a5494b4d826838f94]

NCT01603056 arm group 6f8ce038bc50a5372fcaf86e4b300bb6 [clinicaltrials_resource:NCT01603056/arm-group/6f8ce038bc50a5372fcaf86e4b300bb6]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:245b0106e3be1922b847a6799a540c10

brief summary [clinicaltrials_vocabulary:brief-summary]

Primary aim is to evalu ...... e of Pangramin HDM Mix.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Efficacy and Safety Trial of P ...... use Dust Mite Induced Rhinitis

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

The change from baseline in rhinoconjunctivitis symptoms score at 11 - 12 months between the actively treated patients and the placebo treated. Month 11 and 12. [clinicaltrials_resource:44ce548695ccd30a872cfa932fdcdb6c]

The change from baseline in rhinoconjunctivitis symptoms score at 11 - 12 months between the actively treated patients and the placebo treated. Month 11 and 12. [clinicaltrials_resource:e5fefc4754acd07ca2f9d09cf92ed534]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

The change from baseline in rhinoconjunctivitis symptoms score at 11 - 12 months between the actively treated patients and the placebo treated. Month 11 and 12. [clinicaltrials_resource:17485a83c990f3e85384f5c0deec59b4]

The change from baseline in rhinoconjunctivitis symptoms score at 11 - 12 months between the actively treated patients and the placebo treated. Month 11 and 12. [clinicaltrials_resource:1c478ee082a28512689e90207bc409fc]

The change from baseline in rhinoconjunctivitis symptoms score at 11 - 12 months between the actively treated patients and the placebo treated. Month 11 and 12. [clinicaltrials_resource:1f97ab80ad4f355bfb126a17d68a112c]

The change from baseline in rhinoconjunctivitis symptoms score at 11 - 12 months between the actively treated patients and the placebo treated. Month 11 and 12. [clinicaltrials_resource:2da734ab23f4431f4eee40fbaffff156]

The change from baseline in rhinoconjunctivitis symptoms score at 11 - 12 months between the actively treated patients and the placebo treated. Month 11 and 12. [clinicaltrials_resource:3a10ddc82d68a4e78cca11f253269bc2]

The change from baseline in rhinoconjunctivitis symptoms score at 11 - 12 months between the actively treated patients and the placebo treated. Month 11 and 12. [clinicaltrials_resource:61311825d5958c99e21fcc9457c99e1f]

The change from baseline in rhinoconjunctivitis symptoms score at 11 - 12 months between the actively treated patients and the placebo treated. Month 11 and 12. [clinicaltrials_resource:900e2c642f97a4b94cb5504dc70ab2c3]

The change from baseline in rhinoconjunctivitis symptoms score at 11 - 12 months between the actively treated patients and the placebo treated. Month 11 and 12. [clinicaltrials_resource:9f394a7df15c6e6bc70b153b9ced7006]

The change from baseline in rhinoconjunctivitis symptoms score at 11 - 12 months between the actively treated patients and the placebo treated. Month 11 and 12. [clinicaltrials_resource:b27a0473c6c5be541c64982581077478]

The change from baseline in rhinoconjunctivitis symptoms score at 11 - 12 months between the actively treated patients and the placebo treated. Month 11 and 12. [clinicaltrials_resource:fbf78f2ad4ff8999e7c6d65ee59f7fcb]

completion date [clinicaltrials_vocabulary:completion-date]

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01603056 [clinicaltrials_resource:3563b1541f6bd8ff97052436cfb3742b]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2012-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Pangramin SLIT HDM mix. [clinicaltrials_resource:5ae59dce9341f4fa14cdd525caf098e1]

Placebo [clinicaltrials_resource:d7fd2e161572ce46867ccf0a38bf1645]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

No

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

House dust mite induced allergic rhinitis.

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

ALK-Abelló A/S [clinicaltrials_resource:51036728df08e9dc253fab245e130e6e]

location [clinicaltrials_vocabulary:location]

No.2, Chongwenmennei Street, Dongcheng District [clinicaltrials_resource:8b2a4ddaac27809fcac42d40e017d839]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01603056

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Randomised, Double-blind, Pl ...... initis With or Without Asthma.

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

PS-M-01

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Zhang Luo, Professor [clinicaltrials_resource:a596164a56eda1c9cf10d02735181a22]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

China: Food and Drug Administration [clinicaltrials_resource:f4f0ea17617afc755400c6bca8ea78a5]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

ALK-Abelló A/S [clinicaltrials_resource:51036728df08e9dc253fab245e130e6e]

start date [clinicaltrials_vocabulary:start-date]

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01603056 study design [clinicaltrials_resource:7c0c60d2af196a6ed951324f8a04b9fe]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01603056

verification date [clinicaltrials_vocabulary:verification-date]

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01603056

http://www.w3.org/2001/XMLSchema#string

title

Efficacy and Safety Trial of P ...... use Dust Mite Induced Rhinitis

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Efficacy and Safety Trial of P ...... s [clinicaltrials:NCT01603056]

@en